Embla Medical (EMBLA) Status Update summary

2024 performance highlights

• Achieved strong growth and margin expansion, aligning with the Growth '27 strategy.

• Transitioned to a patient-centric business model, expanding the value chain for chronic mobility challenges.

• Acquired Fior & Gentz, broadening access to patients needing mobility solutions.

• Prosthetics, neuro-orthotics, and patient care segments performed well; bracing segment lagged.

• European operations outperformed other regions.

Strategic milestones and market developments

• U.S. Medicare expanded access to bionic products, marking a major industry milestone.

• Public payers increasingly willing to reimburse for advanced mobility devices, supporting future growth.

• U.S. reimbursement changes expected to accelerate global bionic adoption.

• No anticipated impact from U.S. political changes on reimbursement.

Outlook and priorities for 2025

• Focus on successful launch and performance of new bionic products, with full rollout in 2025.

• Integration of Fior & Gentz acquisition remains a key priority.

• Launching the new patient care brand ForMotion to differentiate and enhance patient care.

• Aiming to leverage U.S. Medicare changes for growth and improved patient access.

• Targets for 2027 include 5%-7% organic growth, 2%-3% M&A growth, and gradual margin expansion.